Of those, 5 RCTs (n = 273 participants) met the inclusion criteria, involving a total of 273 non-diabetic patients with NASH: 142 in the SGLT2 inhibitors group and 131 in the control group, represented as placebo or another antidiabetic drug (pioglitazone or tenegliptin). Here, SLC5A2 is linked to metabolic dysfunction-associated steatohepatitis.